Form 4: Teva Pharmaceutical Industries Executive Matthew Shields Reports Acquisition of Restricted Share Units

EVP, Global Operations at Teva Pharmaceutical Industries, Matthew Shields, reports the acquisition of 69,182 restricted share units.

Summary

• On March 5, 2025, Matthew Shields, EVP, Global Operations at Teva Pharmaceutical Industries, acquired 69,182 restricted share units.
• These restricted share units represent a contingent right to receive one ordinary share or the cash value of one ordinary share.
• The restricted share units vest in installments: 17,295 on each of March 5, 2026, March 5, 2027, and March 5, 2028, and 17,297 on March 5, 2029.
• Following the transaction, Shields beneficially owns 69,182 ordinary shares represented by American Depositary Shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns executive interests with shareholders.

Positives

• The acquisition of restricted share units aligns Matthew Shields' interests with those of Teva's shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted share units.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of restricted share units by a key executive can positively influence shareholder confidence.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates